Thyroidectomy (Thyroid Cancer Surgery)

Total thyroidectomy removes the entire thyroid gland and is recommended for confirmed cancer, larger tumors (>4cm), bilateral disease, or when radioactive iodine therapy is planned. Hemithyroidectomy (lobectomy) removes only one lobe and is appropriate for small, low-risk cancers confined to one side. Total thyroidectomy requires lifelong thyroid hormone replacement, while approximately 70-80% of lobectomy patients maintain adequate thyroid function.

Options include: (1) Open conventional surgery with 2-6cm neck incision - widely available, lower cost; (2) Minimally invasive video-assisted (MIVAT) with smaller incision; (3) Robotic transaxillary via armpit incision - no visible neck scar; (4) TOETVA through the mouth - completely invisible scars; (5) Facelift approach behind the ear. Choice depends on tumor size, cancer stage, patient anatomy, cosmetic preference, and surgeon expertise.

Lobectomy/hemithyroidectomy typically takes 40-90 minutes. Total thyroidectomy takes 1.5-2 hours for straightforward cases, up to 3 hours for complex cases. Surgery with central or lateral neck lymph node dissection requires additional time. Robotic and transoral approaches generally take longer than conventional open surgery.

Differentiated thyroid cancers (papillary and follicular) have excellent prognosis with 5-year survival near 100% and 10-year survival of 95-98%. Medullary thyroid cancer has 93% 5-year survival and 75-95% 10-year survival depending on stage. Anaplastic thyroid cancer is rare but aggressive with approximately 10% 5-year survival. Over 95% of differentiated thyroid cancers achieve complete remission with surgery plus/minus radioactive iodine.

After total thyroidectomy, lifelong levothyroxine (thyroid hormone) replacement is required. Take on an empty stomach, 1 hour before breakfast or 2 hours after eating. Avoid taking with calcium, iron, or antacids (separate by 4 hours). After lobectomy, approximately 20-30% of patients require supplementation if the remaining lobe produces insufficient hormone. TSH levels are checked 4-6 weeks after starting medication.

Hypocalcemia symptoms include numbness or tingling around lips, hands, and feet; muscle cramps or spasms; fatigue; and in severe cases, difficulty breathing or cardiac arrhythmias. These symptoms typically appear 24-72 hours after surgery. Treatment includes oral calcium supplementation (1000-2000mg daily) and vitamin D. Severe cases require IV calcium. Most transient hypocalcemia resolves within 6-12 months.

RAI is strongly recommended for tumors >4cm with extrathyroidal extension, gross extension beyond thyroid, incomplete surgical resection, or distant metastases. It is considered for tumors >2cm with risk factors, lymph node involvement, or aggressive histology. RAI is generally not recommended for low-risk tumors <2cm confined to the thyroid. RAI can be given 4-6 weeks after surgery and requires TSH stimulation.

Surveillance includes thyroglobulin blood tests (tumor marker that should be undetectable after total thyroidectomy), thyroglobulin antibodies, TSH monitoring, and neck ultrasound. First ultrasound is at 6-12 months post-surgery, then periodically based on risk. Thyroglobulin <1.0 ng/mL indicates absence of residual tumor in 98% of patients. Rising levels may indicate recurrence. Surveillance continues lifelong as recurrences can occur decades later.

TOETVA candidates typically have: thyroid gland not excessively large, no history of head/neck surgery or radiation, no lymph node metastasis outside thyroid bed, no extrathyroidal extension to trachea/esophagus, no preoperative vocal cord paralysis, and no substernal thyroid extension. BMI is a relative consideration as elevated BMI makes skin flap elevation more difficult. Oral infections or abscesses are contraindications.

Recommended minimum stay is 10 days. This allows for initial 4-5 days of recovery, first post-operative follow-up appointment, calcium level stabilization monitoring, and addressing any immediate complications. Long-haul flights are generally safe 1-2 weeks after surgery. DVT precautions (compression stockings, walking during flight, hydration) are recommended for flights over 3 hours.

Thailand costs: Lobectomy $3,100-5,000; Total thyroidectomy $7,000-9,000; Robotic surgery up to $12,000 (per verified hospital rates 2025-2026). USA costs: $11,500-25,000+ (per CostHelper/Healthcare Bluebook 2024). Thai pricing is typically all-inclusive (surgeon, anesthesia, hospital stay, basic tests) while US pricing often involves separate bills from surgeon, anesthesiologist, hospital, and pathology. Savings range from 40-75%.

Consider: (1) Tumor characteristics - larger tumors or extensive cancer may require open approach; (2) Cosmetic preference - robotic and TOETVA leave no visible neck scar; (3) Surgeon expertise - outcomes depend on surgeon experience with specific technique; (4) Cost - robotic surgery adds $2,000-5,000; (5) Operative time - minimally invasive approaches take longer; (6) Recovery - similar for most approaches, though minimally invasive may have slightly less pain.

Provide: Complete operative report, pathology report with TNM staging, imaging studies on CD, pre/post-operative lab results, medication list with dosages, recommended TSH target range, thyroglobulin baseline level, RAI recommendation if applicable, long-term surveillance protocol, and Thai medical team contact information. Most Thai hospitals can coordinate directly with your home physician.

No strict age limits exist. Studies show surgery in patients over 75 is as safe as in younger patients with no increase in morbidity and mortality. Age alone is not a contraindication. Pediatric thyroid surgery is performed at specialized centers. Individual assessment considers overall health status, cardiac and respiratory function, ability to tolerate general anesthesia, and life expectancy relative to cancer prognosis.

Recurrence is detected through rising thyroglobulin levels or suspicious findings on neck ultrasound. Most recurrences occur in the first 5 years but can happen decades later. Treatment may include repeat surgery (with higher complication rates), radioactive iodine for iodine-avid disease, external beam radiation, or targeted therapies (lenvatinib, sorafenib) for RAI-refractory advanced disease. Long-term recurrence rate at 30 years is approximately 30%, but cancer death rate is only 8%.